Skip to main content
  • FOR CONSUMERS
  • CONTACT US
Bayer logoMiralax Logo

The information on this page is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL    I AM NOT A HEALTHCARE PROFESSIONAL

Home
  • About MiraLAX®
  • About Constipation
  • Studies & Guidelines
  • GI Survey Results
  • Patient Resources & Samples
Bayer Cross Logo

Triple Action

Triple Action

brand24-triple-action-drop

HYDRATES

brand24-triple-action-drop

SOFTENS

brand24-triple-action-drop

GENTLY RELIEVES1-3

 
brand24-triple-action-drop

HYDRATES

brand24-triple-action-drop

SOFTENS

brand24-triple-action-drop

GENTLY RELIEVES1-3

 

 

MiraLAX Bottle Full label
MiraLAX Bottle Full label

 

 

Start patients on MiraLAX® first

Start patients on MiraLAX® first

MiraLAX® has a triple mechanism of action1-3 and efficacy proven in multiple clinical trials.4-8

Learn More

 

90 percent

 

In a recent survey of 300 GIs,

90% said that MiraLAX® is the OTC laxative they trust most9,a,b

90% said that MiraLAX® is the OTC laxative they trust most9,a,b

aBased on a survey that asked 300 gastroenterologists to rate the important factors in choosing an OTC medication for adults with occasional constipation and how well MiraLAX® met those needs. HCPs selected from a set of options based on their clinical experience. Survey details and data are available upon request.9
bGIs rated the strength of their agreement with this statement ≥5 on a scale of 1-7.9

See Full Results
90percent-icon

Find out a key GI thought leader’s approach to the treatment of occasional constipation

Watch Dr. Darren M. Brenner share some compelling views on occasional constipation and its treatment

  • His individualized approach to patient care
  • His views based upon updated systematic review data and consensus statements8,10,11
  • His thoughts on PEG 3350, the active ingredient in MiraLAX®, as a first-line go-to OTC laxative choice8,10,11 
  • His patients’ experience with fiber laxatives, stool softeners, and stimulant laxatives

Watch Dr. Brenner’s Video to Learn More

Darren M. Brenner

MD, FACG, AGAF, RFF

Professor of Medicine and Surgery, Director—Northwestern Neurogastromotility Program, Northwestern University—Feinberg School of Medicine
Dr. Brenner, a Bayer consultant, has received compensation from Bayer for his participation in this video.
  • His individualized approach to patient care
  • His views based upon updated systematic review data and consensus statements8,10,11
  • His thoughts on PEG 3350, the active ingredient in MiraLAX®, as a first-line go-to OTC laxative choice8,10,11 
  • His patients’ experience with fiber laxatives, stool softeners, and stimulant laxatives

Watch Dr. Brenner’s Video to Learn More

Grade-A-Recommendation-Level-1-Evidence

 

Robust clinical support4-8—Grade A recommendation, Level 1 evidence8

Robust clinical support4-8—Grade A recommendation, Level 1 evidence8

Higher rating than fibers or stool softeners8

In a review spanning more than 2 decades of evidence, MiraLAX® received a stronger recommendation than stool softeners and fiber supplements.8

Watch KOL Video to Learn More
Grade-A-Recommendation-Level-1-Evidence
Blood glucose monitor

CLINICAL CORNER

What’s the link between diabetes and constipation?

What’s the link between diabetes and constipation?

Upwards of 75% of patients with diabetes mellitus report gastrointestinal symptoms12,13; up to 60% have constipation.12,14 Is there a connection? While the exact mechanism might not be known, diabetic neuropathy may play a part.14-16

Explore the Connection
Relief

In a clinical study, patients taking MiraLAX® reported relief in half the time of that reported by those who waited9

In a clinical study, patients taking MiraLAX® reported relief in half the time of that reported by those who waited9

Based on patient-reported complete satisfactory bowel movements (CSBMs) during week 1. For patients taking MiraLAX® (n=148), the median number of days to first experience a CSBM was significantly fewer than (half) that of patients taking placebo (n=64), P=0.001.

*Compared with placebo. Works in 1-3 days.

See Studies & Guidelines

Your patients like these could benefit from starting MiraLAX® sooner

Your patients like these could benefit from starting MiraLAX® sooner

See Their Stories
patient stories

MiraLAX® is supported by 25 years of safe and effective use

It was FDA approved in 1999 as an Rx, and as an OTC product in 2006.17,18

miralax-aga-first-line-pcp
MiraLAX bottle

Recommend MiraLAX® to patients first

Order free samples and
coupons today!

Free Samples & Coupons

patient resources icon

Patient resources

Patient resources

Access downloadable tools to help support your patients.

Learn More

Expand All Collapse All
    References

    References: 1. Schiller LR, Emmett M, Santa Ana CA, Fordtran JS. Osmotic effects of polyethylene glycol. Gastroenterology. 1988;94(4):933-941. doi:10.1016/0016-5085(88)90550-1 2. Hammer HF, Santa Ana CA, Schiller LR, Fordtran JS. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest. 1989;84(4):1056-1062. doi:10.1172/JCI114267 3. Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol. 2011;25(Suppl B):16B-21B. 4. DiPalma JA, Cleveland MvB, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102:1436-1441. doi:10.1111/j.1572-0241.2007.01199.x 5. Cleveland MvB, Flavin DP, Ruben RA, Epstein RM, Clark GE. New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study. South Med J. 2001;94(5):478-481. 6. DiPalma JA, Cleveland MB, McGowan J, Herrera JL. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. South Med J. 2007;100(11):1085-1090. doi:10.1097/SMJ.0b013e318157ec8f 7. Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2010;(7):CD007570. doi:10.1002/14651858.CD007570.pub2 8. Rao SSC, Brenner DM. Efficacy and safety of over-the-counter therapies for chronic constipation: an updated systematic review. Am J Gastroenterol. 2021;116(6):1156-1181. doi:10.14309/ajg.0000000000001222 9. Data on file, Bayer Healthcare. 10. Brenner DM, Corsetti M, Drossman D, Tack J, Wald A. Perceptions, definitions, and therapeutic interventions for occasional constipation: a Rome Working Group consensus document. Clin Gastroenterol Hepatol. 2024;22:397–412. 11. Rao SSC, Brenner DM. Evidence based treatment recommendations for OTC management of chronic constipation. J Am Assoc Nurse Pract.2022;34(9):1041-1044. doi:10.1097/JXX.0000000000000760 12. Piper MS, Saad RJ. Diabetes mellitus and the colon. Curr Treat Options Gastroenterol. 2017;15(4):460-474. doi:10.1007/s11938-017-0151-1 13. Maisey A. A practical approach to gastrointestinal complications of diabetes. Diabetes Ther. 2016;7:379-386. doi:10.1007/s13300-016-0182-y 14. Vinik AI, Erbas T. Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med. 2001;68(11):928-930, 932, 934-944. doi:10.3949/ccjm.68.11.928 15. Ihana-Sugiyama N, Nagata N, Yamamoto-Honda R, et al. Constipation, hard stools, fecal urgency, and incomplete evacuation, but not diarrhea is associated with diabetes and its related factors. World J Gastroenterol. 2016;22(11):3252-3260. doi:10.3748/wjg.v22.i11.3252 16. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553-1579. doi:10.2337/diacare.26.5.1553 17. US Food and Drug Administration. NDA 20-698. Approval letter for MiraLAX powder. February 18, 1999. 18. US Food and Drug Administration. NDA 22-015. Approval letter for MiraLAX powder OTC. October 6, 2006. 19. Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013;144(1):211-217. doi:10.1053/j.gastro.2012.10.029

    violator-desktop
    MiraLAX HCP
    • Contact Us
      • Site Map
      • About MiraLAX®
      • About Constipation
    • Studies & Guidelines
      • GI Survey Results
      • Patient Resources & Samples

    ©2026. All rights reserved. Unless otherwise indicated, all trademarks are owned by Bayer, and its affiliates, or licensed for its use.

    USE AS DIRECTED

    • Bayer Global
    • Bayer US
    • Bayer Consumer Health
    • Conditions of Use
    • Privacy Statement
    • Cookie Settings
    • Imprint
    • California Transparency in Supply Chains
    • Money-Back Guarantee
    • AdChoices
    • Do not sell my personal data
    • Accessibility